Epigenomics Reports Positive Results From Prostate Cancer Study
Posted on: Friday, 17 October 2008, 09:00 CDT
Epigenomics, a cancer molecular diagnostics company, has reported positive final results from its prognostic prostate cancer study.
The clinical study analyzed paraffin embedded tissue samples from 476 prostate cancer patients collected at four major clinical centers in Europe and the US who had undergone radical prostatectomy, with the objective of validating the prognostic utility of Epigenomics's proprietary biomarker, PITX2.
The primary endpoint of the study was to evaluate the methylation status of the PITX2 gene as an independent prognostic biomarker indicative of the risk of prostate cancer biochemical recurrence in patients following removal of the entire prostate, known as radical prostatectomy. This primary endpoint of the study was met by the statistically significant demonstration that patients with elevated PITX2 gene methylation level had a threefold higher risk of relapse following prostatectomy compared to patients with low PITX2 methylation (hazard ratio 3; p less than 0.00005).
As secondary endpoints, the study also analyzed whether measurement of PITX2 methylation adds clinical information to established prognostic parameters such as age, Gleason Score, tumor staging, pre-surgical PSA levels and surgical margin status. In each of the pair wise comparisons of PITX2 with one of these established parameters, high PITX2 gene methylation was an independent prognostic factor indicating more than double the risk compared to patients with low PITX2 gene methylation (hazard ratios greater than 2.3; p less than 0.0001).
In the group of patients with an intermediate Gleason Score of seven, which present difficult decisions for doctors and patients due to difficulty in determining their prognosis, the PITX2 marker was able to discriminate patients into those with a high and low risk of disease recurrence (hazard ratio 2; p=0.005). PITX2 gene methylation remained a statistically significant independent prognostic factor even when it was combined with several established parameters (hazard ratio 1.9; p=0.004) demonstrating its added value in guiding patient management.
The study confirmed the clinical utility of the PITX2 biomarker for prostate cancer prognosis, first established in a 2006 clinical study on 605 prostatectomy tissue samples using real time polymerase chain reaction. In the current study the PITX2 gene methylation was measured reliably using an Affymetrix GeneChip platform, confirming the robustness of the marker across various assay technologies suitable for routine laboratory use.
Following these highly successful results of its clinical study Epigenomics intends to make the PITX2 assay available to clinicians and patients as soon as possible and is exploring several opportunities to commercialize PITX2.
Source: Datamonitor
Related Articles
- NCI Renews Mayo Clinic Cancer Center Support Grant, Extends Comprehensive Status
- Drug Study Shows Activity In Men With Advanced Prostate Cancer
- Novacea's Proof-of-Principle Study of AQ4N in Solid Tumors Published in Clinical Cancer Research
- Introgen Announces Positive Phase 2 Clinical Trial Results With INGN 225 Immunotherapy in Patients With Small Cell Lung Cancer
- Exagen Diagnostics(TM), Inc. Announces an Oral Presentation of a Clinical Study on Genomic Biomarkers for Breast Cancer at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
- Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Glufosfamide in Patients With Platinum-Resistant Ovarian Cancer
- Agendia's MammaPrint(R) Shows Significant Agreement With Other Multi-Gene Breast Cancer Prognosis Tests
- Application of Sentinel Principle in Bladder Cancer Published in Clinical Cancer Research
- Two Clinical Studies Indicate SpectRx Non-Invasive Cervical Cancer Detection Device Accurately Detects Disease While Reducing False Positive Results
- Genes Linked to Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds